| ‘Minority report’: how best to analyze clinical trial data to address disparities DL Hershman, JM Unger Breast cancer research and treatment 118, 519-521, 2009 | 2 | 2009 |
| " MANY VIEWS ON VALUE" OF NATIONAL CANCER INSTITUTE-SPONSORED RANDOMIZED TRIALS V Nghiem, R Vaidya, DL Hershman, M LeBlanc, SD Ramsey, CD Blanke, ... MEDICAL DECISION MAKING 40 (1), E31-E32, 2020 | | 2020 |
| “When offered to participate”: a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials JM Unger, DL Hershman, C Till, LM Minasian, RU Osarogiagbon, ... JNCI: Journal of the National Cancer Institute 113 (3), 244-257, 2021 | 173 | 2021 |
| 1073P Quality of life (QOL) endpoints from the phase III intergroup S1404 adjuvant melanoma trial S Patel, JM Unger, M Othus, A Darke, AA Tarhini, JM Kirkwood, E Sharon, ... Annals of Oncology 32, S890, 2021 | | 2021 |
| 1503O Clinical and scientific impact of National Cancer Institute: Sponsored clinical trial network group treatment trials JM Unger, M LeBlanc, M Bertagnolli, N Wolmark, WJ Curran, PJ O'Dwyer, ... Annals of Oncology 32, S1102-S1103, 2021 | 2 | 2021 |
| A BIOMARKER. DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER A PHASE III RANDOMIZED STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS NIVOLUMAB FOR PREVIOUSLY … M Redman, K Griffin, J Miao, J Moon, J Unger | | |
| A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine … OW Press, JM Unger, LM Rimsza, JW Friedberg, M LeBlanc, ... Clinical Cancer Research 19 (23), 6624-6632, 2013 | 49* | 2013 |
| A comparison of nurses’ and physicians’ perception of cancer treatment burden based on reported adverse events SM Lee, J Miao, R Wu, JM Unger, K Cheung, DL Hershman Health and Quality of Life Outcomes 17, 1-6, 2019 | 2 | 2019 |
| A comparison of oncologist versus mental health provider attitudes towards standardized and tailored patient-reported outcomes SMW Jones, A Gaffney, JM Unger Journal of Patient-Reported Outcomes 5, 1-10, 2021 | | 2021 |
| A Ground’s-Eye View on Racial and Ethnic Disparities in Cancer Clinical Trial Participation JM Unger JAMA Network Open 6 (7), e2322436-e2322436, 2023 | 2 | 2023 |
| A multi center trial of hyperCVAD plus rituxan in patients with newly diagnosed mantle cell lymphoma EM Epner, J Unger, T Miller, L Rimza, C Spier, M Leblanc, R Fisher Blood 110 (11), 121A-121A, 2007 | 26 | 2007 |
| A multi center trial of hyperCVAD+ Rituxan in patients with newly diagnosed mantle cell lymphoma. EM Epner, J Unger, T Miller, L Rimzsa, C Spier, M Leblanc, R Fisher Blood, The Journal of the American Society of Hematology 110 (11), 387-387, 2007 | 57 | 2007 |
| A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group … OW Press, JM Unger, RM Braziel, DG Maloney, TP Miller, M LeBlanc, ... Blood 102 (5), 1606-1612, 2003 | 214 | 2003 |
| A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430 JA Sosman, J Moon, RJ Tuthill, JA Warneke, JT Vetto, BG Redman, ... Cancer 117 (20), 4740-4746, 2011 | 199 | 2011 |
| A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B … AT Stopeck, JM Unger, LM Rimsza, M LeBlanc, B Farnsworth, M Iannone, ... Blood, The Journal of the American Society of Hematology 120 (6), 1210-1217, 2012 | 66 | 2012 |
| A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213 SH Bernstein, E Epner, JM Unger, M Leblanc, E Cebula, R Burack, ... Annals of Oncology 24 (6), 1587-1593, 2013 | 168 | 2013 |
| A phase II trial of CHOP followed by Bexxar (TM)(tositumomab and iodine-131-tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas (SWOG 9911). OW Press, JM Unger, RM Braziel, DG Maloney, ML LeBlanc, TM Grogan, ... Blood 98 (11), 843A-844A, 2001 | 13 | 2001 |
| A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkin's lymphoma: SWOG 9800 M DG Blood 98, 843a, 2001 | 35 | 2001 |
| A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy–Southwest Oncology Group study RP Whitehead, JM Unger, LE Flaherty, EH Kraut, GM Mills, CE Klein, ... Investigational new drugs 20, 105-111, 2002 | 10 | 2002 |
| A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108 AT Stopeck, JM Unger, LM Rimsza, WT Bellamy, M Iannone, DO Persky, ... Leukemia & lymphoma 50 (5), 728-735, 2009 | 119 | 2009 |